1. Why the Generic Market Runs on Partnerships, Not Margins Generics and biosimilars filled 90% of all U.S. prescriptions dispensed […]

Executive Framing: The Cost Problem That Waste Built {#executive-framing} Generic drugs fill roughly nine out of every ten prescriptions dispensed

Section 1: The Modern API Manufacturing Landscape 1.1 What an API Is, and Why Its Manufacturing Process Is a Core

I. Executive Summary Key Takeaways The global CDMO market is on track to reach $465 billion by 2032, driven by

Generic drugs account for roughly 91% of all U.S. prescriptions filled while representing only about 18% of total drug spend.

A deep-dive reference for pharma/biotech IP teams, R&D leads, and institutional investors operating in or sourcing from the European market.

1. The Market Structure Forcing Manufacturing Innovation The global generic drug market generated approximately $245 billion in 2020 and is

1. The Strategic Stakes: Why Your CDMO Model Choice Determines IP Value, Not Just Cost The question most pharmaceutical executives

Introduction: The Strategic Imperative of Project Management in the Modern CDMO Ecosystem The pharmaceutical and biotechnology industries operate at the